drugset
Drugs / Recombinant two-component COVID-19 vaccine (CHO cell)
last change Apr 2024 re-read 3 minutes ago

Recombinant two-component COVID-19 vaccine (CHO cell)

Vaccine

Developed for
COVID-19
Investigated by
Jiangsu Rec-Biotechnology Co., Ltd.

Trials 2

today NCT05398848 · Ph 3 NCT05323435 · Ph 2
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT05323435 May → Jul 2022 COVID-19 Jiangsu Rec-Biotechnology Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT05398848 Oct 2022 → Sep 2023 COVID-19 Jiangsu Rec-Biotechnology Co., Ltd. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Recombinant two-component COVID-19 vaccine (CHO cell) ClinicalTrials.gov intervention name — accepted as the source's own label NCT05398848 ↗
1

NCT05323435 ↗
Modality Vaccine “Recombinant protein vaccines are vital for broad protection against SARS-CoV-2 variants.” PMID 38529685 ↗ Apr 2024
Route Intramuscular “Three-dose intramuscular (IM) vaccination schedule” NCT05398848 ↗